Loren Data's SAM Daily™

FBO DAILY ISSUE OF SEPTEMBER 06, 2002 FBO #0278
SOLICITATION NOTICE

A -- Evaluation of BRCA2 in the genetic susceptibility of familial esophagel squamous cell carcinoma

Notice Date

9/4/2002
 

Notice Type

Solicitation Notice
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
 

ZIP Code

20852
 

Solicitation Number

NCI-20139-NG
 

Point of Contact

Malinda Holdcraft, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Caren Rasmussen, Lead Contract Specialist, Phone (301) 402-4509, Fax (301) 402-4513,
 

E-Mail Address

holdcram@exchange.nih.gov, cr214i@nih.gov
 

Description

The National Cancer Institute (NCI), Cancer Prevention Studies Branch (CPSB), to procure supplies and services from Myriad Genetic Laboratories, 320 Wakara Way, Salt Lake City, Utah 84108 for the Evaluation of BRCA2 in the genetic susceptibility of familial esophageal squamous cell carcinoma (ESCC). The supplies and services herein are commercial as defined in FAR Part 13, and are being procured using simplified procedures. The North American Industry Classification System code is 541710 and the business size standard is 500 employees. Cancer Prevention Studies Branch, CPSB requires services to sequence the BRCA2 gene in the blood of 50 ESCC cases as part of our efforts to determine the frequency of germline BRCA2 mutations in ESCC patients and compare the frequency of these mutations between ESCC cases with and without a family history of upper gastrointestinal cancer. Previously we have shown that BRCA2 mutations occur with low to moderate frequency in ESCC tumors themselves and, through previous testing at Myriad Genetics, have identified several germline alterations (including both polymorphisms and mutations) in ESCC cases and their family members. Myriad Genetics holds a patent on the BRCA2 genetic sequence and the commercial testing of this sequence in blood samples. Period of Performance: upon award of purchase order through 12 months, FAR Clause 52.217-8 Option to Extend Services (November 1999) applies to this requirement. Myraid Genetics is the only source known to the NCI that holds a patent on the BRCA2 sequence. Therefore, the standard reference laboratory for BRCA2 sequencing and the only available commercial laboratory offering this test. Changing variables at this time will interrupt correct interpretation of experiment in progress. This is not a request for competitive quotations. However, if any interested party believes it can perform the above requirement, it may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient detail to allow NCI to determine if it can meet the above minimum specifications described herein. Capability statements must be received in the Contracting Office by 1:00 PM EDT (local Washington D.C. time) on September 11, 2002. If you have questions, please contact Malinda Holdcraft, Purchasing Agent via electronic mail at holdcram@excange.nih.gov or by fax at (301) 402-4513. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received shall be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted.
 

Place of Performance

Address: NIH/NCI, 9000 Rockville Pike, Bethesda,MD

Zip Code: 20892

Country: USA
 

Record

SN00157330-W 20020906/020904213406 (fbodaily.com)
 

Source

FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |